Veritas Genetic participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients
Comunicato Precedente
Comunicato Successivo
Key Findings of the Study
The study, published in the Journal of Personalized Medicine, evaluated women with a family history of breast cancer, demonstrating that PRS significantly improves the accuracy of individual risk prediction. This is particularly relevant for women who are non-carriers of pathogenic variants in susceptibility genes. For carriers of mutations in genes like BRCA1 and BRCA2, PRS offers a complementary approach that helps refine personalized management and prevention strategies.
According to Dr. Izquierdo, Chief Medical Officer at Veritas, "This study reaffirms the clinical value of genomic tools in personalizing preventive medicine. The use of PRS, along with traditional genetic evaluation, allows healthcare professionals to offer more precise and tailored care to the individual needs of each patient, ultimately improving long-term outcomes."
An Essential Tool for Personalized Medicine
PRS has the potential to transform how cancer risk is assessed and managed in patients with a family history of the disease. Dr. Izquierdo, added: "Polygenic risk scoring not only provides a deeper evaluation of genetic risk but also redefines how we understand cancer susceptibility in families with a history of the disease. This tool is key to the future of personalized medicine and the proactive management of complex conditions like breast cancer."
About Veritas Genetics
Veritas Genetic leads the implementation of advanced genomic solutions, focusing on preventive and personalized medicine. Through partnerships with top-tier academic institutions, Veritas continues to drive innovation aimed at improving health and well-being.
View original content:
